Nosofedril 30mg/4mg Tablets | Amros Pharmaceuticals

Description

Nosofedril 30mg/4mg Tablets contain Pioglitazone and Glimepiride, a fixed-dose combination of two oral antidiabetic agents.

Pioglitazone belongs to the thiazolidinedione class and improves insulin sensitivity, helping the body respond more effectively to insulin.

Glimepiride is a sulfonylurea that stimulates insulin release from pancreatic beta cells, helping reduce elevated blood glucose levels.

The combination provides complementary antihyperglycemic effects and may be prescribed when treatment with both medicines is appropriate.

Nosofedril 30mg/4mg contains a higher dose of Glimepiride than Nosofedril 30mg/2mg. The choice of strength depends on the patient’s existing diabetes treatment, glycemic response, tolerability and risk of hypoglycemia.

The medicine is intended for use alongside diet, exercise and regular monitoring of blood glucose levels.

Verified Therapeutic Indications

• Improvement of glycemic control in adults with type 2 diabetes mellitus.

• Patients requiring combined Pioglitazone and Glimepiride treatment.

• Replacement of separately prescribed Pioglitazone and Glimepiride at equivalent doses, where clinically appropriate.

Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.

Dosage & Administration

Reference prescribing information describes administration once daily with the first main meal.

The 30mg/4mg strength may be selected when the patient’s previous treatment and glucose response support this dosage. It should not automatically replace the 30mg/2mg formulation.

Dose adjustments must be made by the treating physician after assessing glycemic control and adverse effects.

Possible Side Effects

• Hypoglycemia, potentially severe.

• Weight gain and peripheral edema.

• Headache and dizziness.

• Upper respiratory tract symptoms.

• Nausea and gastrointestinal discomfort.

Serious risks include congestive heart failure, liver injury, severe allergic reactions and possible bladder cancer risk associated with Pioglitazone.

Contraindications & Precautions

Heart failure: Pioglitazone can cause fluid retention and worsen congestive heart failure. Initiation is contraindicated in patients with established NYHA Class III or IV heart failure and is not recommended for patients with symptomatic heart failure.

Hypoglycemia: Glimepiride may cause severe low blood glucose, particularly in older adults, patients with kidney impairment or those who miss meals.

Bladder cancer: Avoid use in patients with active bladder cancer and carefully assess treatment in those with a previous history.

Liver function: Obtain liver tests before beginning therapy.

Drug interactions: Strong CYP2C8 inhibitors such as gemfibrozil can substantially increase Pioglitazone exposure. The 30mg fixed-dose combination is generally unsuitable when a maximum Pioglitazone dose of 15mg is required.

Pregnancy and breastfeeding: Require individual medical assessment; this combination is not a routine treatment choice during pregnancy.

Storage Instructions

Follow Nosofedril’s approved product-label storage requirements. Brand-specific temperature and handling instructions have not been verified.